Open AccessType 1 diabetes mellitus in a melanoma patient treated with adjuvant nivolumab therapy
Author(s) -
Maeda Takuya,
Kitamura Shinya,
Yanagi Teruki,
Narahira Atsushi,
Miyamoto Kodai,
Hata Hiroo,
Cho kyu Yong,
Kameda Hiraku,
Nakamura Akinobu,
Shimizu Hiroshi
Publication year - 2019
Publication title -
journal of cutaneous immunology and allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.127
H-Index - 1
ISSN - 2574-4593
DOI - 10.1002/cia2.12085
Subject(s) - medicine , nivolumab , adjuvant therapy , adverse effect , adjuvant , melanoma , type 1 diabetes , diabetes mellitus , nodule (geology) , lymph node , surgery , oncology , dermatology , cancer , immunotherapy , cancer research , endocrinology , paleontology , biology
Although there have been also known that a few cases may develop T1DM during adjuvant use of programmed death‐1 inhibitors, its clinical course has not ever been described in detail. This report presents the case of type 1 diabetes mellitus related to adjuvant nivolumab therapy.